Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease

Joseph H. Friedman, Robert M. Berman, Christopher G. Goetz, Stewart A. Factor, William G. Ondo, Joanne Wojcieszek, William H. Carson, Ronald N. Marcus

Research output: Contribution to journalArticle

108 Citations (Scopus)

Abstract

Psychosis affects at least 5% to 8% of medication-treated patients with idiopathic Parkinson's disease (PD). Treatment options include reducing medications used for the treatment of PD-related motor symptoms or introducing an atypical antipsychotic drug. Only clozapine has been demonstrated to be efficacious and tolerated in double-blind controlled trials. This study evaluated the effect of aripiprazole, an atypical antipsychotic, on psychosis in PD in an open-label pilot study. Fourteen patients meeting entry criteria were started on aripiprazole 1 mg/day and titrated up to a maximum dose of 5 mg as needed. Subjects were evaluated on the Unified Parkinson's Disease Rating Scale (UPDRS) part III for motor function, the Neuropsychiatric Inventory (NPI), and the Brief Psychiatric Rating Scale (BPRS) for psychiatric response. Statistically significant improvement in mean BPRS and positive BPRS subscales occurred with open-label aripiprazole, but eight subjects discontinued the study due to worsened Parkinsonism (three), worsened psychosis (two), worsening of both (two), and lack of efficacy (one). While some patients had a favorable response, aripiprazole was associated with an exacerbation of motor symptoms. In this small study on psychosis in PD, aripiprazole did not appear promising.

Original languageEnglish
Pages (from-to)2078-2081
Number of pages4
JournalMovement Disorders
Volume21
Issue number12
DOIs
StatePublished - Dec 2006

Fingerprint

Psychotic Disorders
Parkinson Disease
Brief Psychiatric Rating Scale
Safety
Antipsychotic Agents
Clozapine
Parkinsonian Disorders
Psychiatry
Aripiprazole
Equipment and Supplies
Therapeutics

Keywords

  • Aripiprazole
  • Atypical antipsychosis drugs
  • Delusions
  • Drug-induced psychosis in Parkinson's disease
  • Hallucinations
  • Parkinson's disease
  • Parkinson's phychosis
  • Secondary psychosis

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease. / Friedman, Joseph H.; Berman, Robert M.; Goetz, Christopher G.; Factor, Stewart A.; Ondo, William G.; Wojcieszek, Joanne; Carson, William H.; Marcus, Ronald N.

In: Movement Disorders, Vol. 21, No. 12, 12.2006, p. 2078-2081.

Research output: Contribution to journalArticle

Friedman, Joseph H. ; Berman, Robert M. ; Goetz, Christopher G. ; Factor, Stewart A. ; Ondo, William G. ; Wojcieszek, Joanne ; Carson, William H. ; Marcus, Ronald N. / Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease. In: Movement Disorders. 2006 ; Vol. 21, No. 12. pp. 2078-2081.
@article{e785468d49434d39a5df486ecff0b51a,
title = "Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease",
abstract = "Psychosis affects at least 5{\%} to 8{\%} of medication-treated patients with idiopathic Parkinson's disease (PD). Treatment options include reducing medications used for the treatment of PD-related motor symptoms or introducing an atypical antipsychotic drug. Only clozapine has been demonstrated to be efficacious and tolerated in double-blind controlled trials. This study evaluated the effect of aripiprazole, an atypical antipsychotic, on psychosis in PD in an open-label pilot study. Fourteen patients meeting entry criteria were started on aripiprazole 1 mg/day and titrated up to a maximum dose of 5 mg as needed. Subjects were evaluated on the Unified Parkinson's Disease Rating Scale (UPDRS) part III for motor function, the Neuropsychiatric Inventory (NPI), and the Brief Psychiatric Rating Scale (BPRS) for psychiatric response. Statistically significant improvement in mean BPRS and positive BPRS subscales occurred with open-label aripiprazole, but eight subjects discontinued the study due to worsened Parkinsonism (three), worsened psychosis (two), worsening of both (two), and lack of efficacy (one). While some patients had a favorable response, aripiprazole was associated with an exacerbation of motor symptoms. In this small study on psychosis in PD, aripiprazole did not appear promising.",
keywords = "Aripiprazole, Atypical antipsychosis drugs, Delusions, Drug-induced psychosis in Parkinson's disease, Hallucinations, Parkinson's disease, Parkinson's phychosis, Secondary psychosis",
author = "Friedman, {Joseph H.} and Berman, {Robert M.} and Goetz, {Christopher G.} and Factor, {Stewart A.} and Ondo, {William G.} and Joanne Wojcieszek and Carson, {William H.} and Marcus, {Ronald N.}",
year = "2006",
month = "12",
doi = "10.1002/mds.21091",
language = "English",
volume = "21",
pages = "2078--2081",
journal = "Movement Disorders",
issn = "0885-3185",
publisher = "John Wiley and Sons Inc.",
number = "12",

}

TY - JOUR

T1 - Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease

AU - Friedman, Joseph H.

AU - Berman, Robert M.

AU - Goetz, Christopher G.

AU - Factor, Stewart A.

AU - Ondo, William G.

AU - Wojcieszek, Joanne

AU - Carson, William H.

AU - Marcus, Ronald N.

PY - 2006/12

Y1 - 2006/12

N2 - Psychosis affects at least 5% to 8% of medication-treated patients with idiopathic Parkinson's disease (PD). Treatment options include reducing medications used for the treatment of PD-related motor symptoms or introducing an atypical antipsychotic drug. Only clozapine has been demonstrated to be efficacious and tolerated in double-blind controlled trials. This study evaluated the effect of aripiprazole, an atypical antipsychotic, on psychosis in PD in an open-label pilot study. Fourteen patients meeting entry criteria were started on aripiprazole 1 mg/day and titrated up to a maximum dose of 5 mg as needed. Subjects were evaluated on the Unified Parkinson's Disease Rating Scale (UPDRS) part III for motor function, the Neuropsychiatric Inventory (NPI), and the Brief Psychiatric Rating Scale (BPRS) for psychiatric response. Statistically significant improvement in mean BPRS and positive BPRS subscales occurred with open-label aripiprazole, but eight subjects discontinued the study due to worsened Parkinsonism (three), worsened psychosis (two), worsening of both (two), and lack of efficacy (one). While some patients had a favorable response, aripiprazole was associated with an exacerbation of motor symptoms. In this small study on psychosis in PD, aripiprazole did not appear promising.

AB - Psychosis affects at least 5% to 8% of medication-treated patients with idiopathic Parkinson's disease (PD). Treatment options include reducing medications used for the treatment of PD-related motor symptoms or introducing an atypical antipsychotic drug. Only clozapine has been demonstrated to be efficacious and tolerated in double-blind controlled trials. This study evaluated the effect of aripiprazole, an atypical antipsychotic, on psychosis in PD in an open-label pilot study. Fourteen patients meeting entry criteria were started on aripiprazole 1 mg/day and titrated up to a maximum dose of 5 mg as needed. Subjects were evaluated on the Unified Parkinson's Disease Rating Scale (UPDRS) part III for motor function, the Neuropsychiatric Inventory (NPI), and the Brief Psychiatric Rating Scale (BPRS) for psychiatric response. Statistically significant improvement in mean BPRS and positive BPRS subscales occurred with open-label aripiprazole, but eight subjects discontinued the study due to worsened Parkinsonism (three), worsened psychosis (two), worsening of both (two), and lack of efficacy (one). While some patients had a favorable response, aripiprazole was associated with an exacerbation of motor symptoms. In this small study on psychosis in PD, aripiprazole did not appear promising.

KW - Aripiprazole

KW - Atypical antipsychosis drugs

KW - Delusions

KW - Drug-induced psychosis in Parkinson's disease

KW - Hallucinations

KW - Parkinson's disease

KW - Parkinson's phychosis

KW - Secondary psychosis

UR - http://www.scopus.com/inward/record.url?scp=33846447413&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846447413&partnerID=8YFLogxK

U2 - 10.1002/mds.21091

DO - 10.1002/mds.21091

M3 - Article

VL - 21

SP - 2078

EP - 2081

JO - Movement Disorders

JF - Movement Disorders

SN - 0885-3185

IS - 12

ER -